GoodFellas Big Board Catalyst and Chart Plays

[beach_trades]

IBIO DD: Why I Like this stock and Insider(s)

This is my buy and hold biotech stock (add on dips)

Hiring of Jules Musing in December

NEWARK, Del., Dec. 7, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced that Jules A. Musing, an iBio Director, will assume a role as a Managing Director of the Company for at least the next six months in order to accelerate the Company's business development activity. Mr. Musing, formerly a Senior Executive at Johnson & Johnson, joined iBio's Board of Directors in June of 2011. In the course of his career in the Pharmaceutical and Biotechnology Industry, Mr. Musing has been President and Managing Director for Johnson & Johnson, Janssen Pharmaceutica, and Ares Serono companies. At Johnson & Johnson, Mr. Musing was also responsible for worldwide licensing and acquisition of pharmaceutical and biotechnology products and technologies and the establishment of strategic alliances. His activities included the establishment of new scientific and product collaborations in various therapeutic areas, the negotiation of licensing and alliance agreements with biotechnology and pharmaceutical companies worldwide, and the partnering, spin-out and out-licensing of company pharmaceutical and biotechnology assets.

In his role as an iBio Managing Director, Mr. Musing will focus on the Company's business development and licensing activities, including direct dealings with third parties and development of human and material resources to enlarge the Company's business development capacity. "Jules will help us expand our business development capability rapidly to deal with the product candidates already developed on our platform and those we expect in the next few months," said Robert B. Kay, iBio's Chairman and CEO. "We expect Jules' experience as a deal maker and his access to senior management in potential users of our technologies to lead to important business opportunities for us in a variety of U.S. and international markets. We are most fortunate to have his participation during this stage of our growth."
http://www.knobias.com/story.htm?eid=3.1.8a4a7f49d9373801ed4f607aa414e408ef421717541d30ac2d1e940b149d1b3c

MCKEY JOHN D JR whom owned 779.104 added 100,000 shares in January

13-Jan-12 100,000 IBIO Purchase at $0.65 per share.
(Cost of $65,000)

http://biz.yahoo.com/t/00/783.html

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8003032

Eastern Capital 10 million share stake in January taken

13-Jan-12 10,000,000 IBIO Statement of Ownership

http://biz.yahoo.com/t/89/8259.html

iBio listing deficiency resolved January 27, 2012
iBio announced that the NYSE Amex confirmed positive resolution of the company's previously noted listing deficiency with respect to Section 10031i) of the NYSE Amex company guide.

iBIO Market Oppurtunity (click on link)

http://ibioinc.com/home/products/